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Background and Objectives: Fourfold increases in opioid prescrib-
ing and dispensations over 2 decades in the U.S. has paralleled
increases in opioid addictions and overdoses, requiring new
preventative, diagnostic, and treatment strategies. This study examines
Prescription Drug Monitoring Program (PDMP) tracking as a novel
measure of opioid addiction treatment outcomes in a university-
afﬁliated integrated mental health-addiction treatment clinic.
Methods: Repeated measure parametrics examined PDMP and urine
drug screening (UDS) data before and after ﬁrst injection for all
patients (N¼ 68) who received at least one long-acting naltrexone
injection (380mg/IM) according to diagnostic groupings of having
either (i) alcohol (control); (ii) opioid; or (iii) combined alcohol and
opioid use disorders.
Results: There were no group differences post-injection in treatment
days, injections delivered, or treatment service encounters. UDS and
PDMP measures of opioid exposures were greater in opioid
compared to alcohol-only patients. Post-ﬁrst injection, UDS’s
positive for opioids declined (p< .05) along with PDMP measures
of opioid prescriptions (p< .001), doses (p< .01), types (p< .001),
numbers of dispensing prescribers (p< .001) and pharmacies
(p< .001). Opioid patients without alcohol disorders showed the
best outcomes with 50% to 80% reductions in PDMP-measures of
opioids, down to levels of alcohol-only patients.
Conclusions: This study shows PDMP utility for measuring opioid
addiction treatment outcomes, supporting the routine use of PDMPs
in clinical and research settings.
Scientiﬁc Signiﬁcance: These ﬁndings demonstrate that opioid
addiction in patients with complex addictions and mental illnesses
comorbidities can show effective treatment responses as measured by
PDMP tracking of decreases in opioid prescriptions to those patients.
(Am J Addict 2016;25:557–564)
INTRODUCTION
From 1999 to 2008, the U.S. has experienced a fourfold
increase in opioids prescribed and dispensed for pain
indications, with proportional increases in addiction treatment
episodes and prescription drug overdose deaths.1 By 2008,
prescription drug overdoses were occurring at rates nearly
twofold higher than overdoses caused by heroin and all other
illicit drugs combined, surpassing U.S. death rates caused by
car accidents, suicides, or homicides.1 In 2010, annual health
care expenditures nationwide, just for treating overdoses, but
not addiction, reached $2.3 billion, nearly double the annual
extramural budget of the National Institutes on Drug Abuse.2
This public health crisis, listed as an epidemic by the CDC,3
has been linked to medical-cultural shifts happening over
2 decades that have promoted opioid prescribing from
primary care doctors and specialists, at increased doses, in
poly opioid combinations, for greater durations, and in more
clinical contexts.4–6 Although the health, economic, and social
consequences of the prescription opioid epidemic are broad,7,8
people with mental illness and non-opioid addictions show
disproportionate risk of suffering serious complications of
increased access to prescription opioids.9–12 Pre-existing mental
illness is major risk factor for acquisition of opioid use disorders,
and non-medical opioid use that escalates to addiction is a
risk factor for onset of mental illness.13 Whether produced by
“Adverse Selection” where doctors are more likely to prescribe
high risk opioid regimens to high risk (eg, mentally ill/addicted)
patients,14,15 or biological vulnerability to addictions in mentally
ill brains,16,17 strong linkages between mental illness and opioid
addictions indicate the need to recognize and treat prescription
opioid addictions in behavioral health settings.
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Prescription Drug Monitoring Programs (PDMPs) are
state-supported databases that allow instant access to outpa-
tient controlled drug prescriptions and dispensation records.
PDMPs are important new tools for preventing dangerous
addictive drug prescribing, and for diagnosing and treating
opioid addictions.11,18 Our prior study using Indiana’s
PDMP (INSPECT: INdiana Scheduled Prescription Electronic
Collection and Tracking) demonstrated PDMP utility as a
diagnostic tool and for identifying detrimental opioid
prescribing to mentally ill/addicted patients.11 The present
study extends these ﬁndings, by showing that PDMP inquiry
can be utilized as a repeated measure for treatment outcome
monitoring. We examined a population of patients selected by
the sole criterion that they had received one or more doses of
long-acting injectable naltrexone (INTX) (trade name Vivi-
trol; 380mg IM) within a 12-month study window, for FDA-
approved indications of opioid and/or alcohol use disorder.19
The study cohort of 68 patients was thus naturalistically
composed of three subgroups determined by their INTX
diagnostic indication of having either (i) alcohol; (ii) opioid, or
(iii) combined alcohol and opioid use disorders. This design, in
which alcohol patients without opioid use disorders served as a
control group, allowed us to examine the diagnostic speciﬁcity
and utility of longitudinal PDMP data for opioid treatment
outcome measurement, simultaneous with, and in comparison
to urine drug screening, in a clinically realistic cohort of
patients complicated by a diversity of comorbid addictions and
mental illnesses.
METHODS
Setting, Study Population, and Design
The study took place in an integrated dual diagnosis
outpatient clinic of Midtown-Eskenazi, the major community
mental health center of downtown Indianapolis, IN, which
hosts the addiction psychiatry fellowship training program of
Indiana University Department of Psychiatry. It carries a
census of 250–350 patients, referred from families, child
protective services, probation courts, and health care facilities
throughout Indianapolis. The clinic is staffed by a multidisci-
plinary team of nurses, masters-level therapists, case
managers, board-certiﬁed addiction psychiatrists, addiction
psychiatry fellows, and residents. It provides comprehensive-
integrated dual diagnosis treatment to all patients without
referring them out, regardless of what mental illness and
addiction combination they may have; all of the patients
included in this studywere engaged, in an individualizedway, in
fully integrated dual diagnosis care involving both medication
and psychotherapeutic treatments (including individual and
group therapies) for both mental illness and addiction.
Data Collection
Medical record and PDMP data were collected for all
patients that had been diagnosed by the addiction psychiatrist
(or fellows and residents under their supervision) using
DSM-IV criteria, and treated for the indication(s) of alcohol
and/or opioid use disorder with at least one injection of long-
acting injectable naltrexone (INTX) (Vivitrol; 380mg IM)
between August 1, 2012 and August 1, 2013. Data tracking
ended for all cases on September 1, 2013. No patients had
previously received any prior INTX injections, and none had
treatment histories at the VA. There were no exclusions based
on any demographic or diagnostic comorbidity. The study was
designed as a before and after comparison, anchored on the
date of the ﬁrst INTX injection, between three naturalistically
formed INTX indication groups composed of patients with: (i)
alcohol (ETOH); (ii) opioid (OP); or (iii) both opioid and
alcohol use disorders (OPþETOH). Following the template
of our prior PDMP study,11 we collected key demographic and
physician-assessed diagnostic data (Axis I mental health and
substance diagnoses, Axis II disorders), concurrent with the
time of ﬁrst INTX injection, which was generally one of the
ﬁrst appointments with the psychiatrist. Chart review also
provided number of treatment service encounters (individual
or group sessions, including therapist, nursing, and doctor’s
appointments), and total number of INTX injections. Key
outcome data collected for time periods before and after ﬁrst
INTX injection (pre- vs. post-injection phases) included urine
drug screening (Redwood Laboratories, Santa, Rosa, CA;
testing for up to 10 different substances including morphine,
codeine, hydrocodone, oxycodone, buprenorphine, metha-
done, amphetamine, cocaine, tetrahydrocannabinol (THC),
and Ethylglucoronide (ETG), a direct metabolite of ETOH20),
and PDMP data (INSPECT). INSPECT provided a record of
controlled substance outpatient prescribing (types, quantities,
dates of prescription and ﬁlls, prescribers and pharmacies)
dispensed from all Indiana retail pharmacies (except not from
Indiana’s Veterans Administration pharmacies in Indiana, or
methadone dispensed frommethadone treatment programs for
opioid use disorders, which at the time of this study, still had
not become transparent to INSPECT).11
For all subjects, the pre-injection phase was deﬁned as the
span of 1 year prior to the date of ﬁrst INTX injection. This
phase mostly encompassed time when patients had not yet
entered treatment in our clinic, as well as about 2 months from
the time they had entered treatment (eg, undergoing
detoxiﬁcation and/or starting individual and group therapies)
to when they were ﬁrst evaluated by a psychiatrist, which was
required for starting INTX. The post-injection phase spanned
time from the ﬁrst INTX injection to the closing date of the
study. Unlike the 1-year pre-injection phase, the post-injection
phase was of variable durations between subjects, averaging
7 months when patients were engaged in care. This study
was evaluated and approved by the IU School of Medicine
Institutional Review Board.
Data Analysis
Analysis of the post-injection treatment parameters (days
post injection, number of injections, service encounters)
was conducted as simple One-way Analyses of Variance
(ANOVAs), where the independent factor (INTX indication
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group) had three levels (ETOH only; OP only; OPþETOH).
For analysis of PDMP and UDS data, we utilized a mixed
model, Repeated Measures ANOVA; dependent measures
were compared across the pre- versus post-injection phases
according to the INTX indication group factor. Analysis of
UDS data looked at percentages of UDS tests collected that
were positive, since frequencies of UDS testing were variable
between patients, and the pre-injection phase encompassed
much time when patients were not in treatment. This analysis
was conducted ﬁrst, for all individual tests among all 10
substances tested (including 6 opioids and amphetamines,
cocaine, THC and ETG); second, for ETG tests only; and third,
for tests of the 6 opioids only (morphine, codeine, hydro-
codone, oxycodone, buprenorphine, methadone). For PDMP
data, raw numbers of opioid prescriptions and opioid pills
dispensed were adjusted in the post-injection phase to rates/
year, to account for differences in durations in the pre- versus
post-injection phases across patients (eg, if the post-injection
phase was 9 months in duration, the raw values were divided
by .75 years). Consistent with our prior study11 we did not
translate the quantities of prescribed opioids to morphine
equivalents. The raw data for opioid pills dispensed showed
extreme right-skewing, so this data was further transformed to
log base 2 (of opioid pills) for parametric testing. PDMP
outcome measures that tended to be stable (ie, did not increase
linearly with time, including # of different generic types of
opioids prescribed, different prescribers, different pharma-
cies) were directly compared pre- and post-injection without
adjustment. Signiﬁcant interactions between the repeated
measure and group were followed up as One-way, single-level
repeated measure ANOVAs, to specify which group showed
the most signiﬁcant change from pre to post-injection phases.
All data in tables and graphs are reported as meansþSEMS
with all signiﬁcant (p< .05) results presented throughout
along with key non-signiﬁcant (NS) results.
RESULTS
Demographics and Diagnostic Spectrum
The study population (N¼ 68) was 59% female, about two
thirds white, and two-thirds uninsured (ie, with no insurance,
where Midtown-Eskenazi bore the cost of care) (Table 1).
Over half the patients were between ages of 26 and 45 years. A
large majority (91%) had some type of Axis 1 non-substance
disorder, with unipolar depression diagnosed most often, 66%
of cases. Axis II conditions were diagnosed in 37% of cases,
with Personality Disorder NOS found most frequently (22%).
All patients were diagnosed with a substance use disorder with
53% having ETOH but not opioid use disorder, 28% having
opioid use disorder without ETOH use disorder, and 18%
having both. Tobacco use disorder was the second most
common addiction in the population, found in 59%, second
only to ETOH use disorder (72%), and exceeding opioid
(47%) and cannabis use disorders (35%). The population had a
high degree of comorbidity (Table 2) with a majority of having
3 or more addictions, and 2 or more mental illnesses. Five or
more DSM-IV diagnoses were found in 40% of the study
population, while much smaller minorities had no diagnosable
axis I or II mental illness (7%) or only addiction involving just
one substance (21%).
Treatment Groups
Among n¼ 32 patients with opioid use disorder, 17 had
been using heroin and prescription opioids (10 in the opioid
only group; 7 in opioid and ETOH group) while the remaining
15 had used prescription opioids only. Of these n¼ 32, 7 had
also been prescribed buprenorphine at some point in the pre-
TABLE 1. Demographics and clinical diagnoses of study population
(N¼68)
Demographic n (%)
Age
25 y 5 (7)
26–45 y 37 (54)
>45 y 26 (38)
Gender
Female 40 (59)
Male 28 (41)
Ethnicity
Black 23 (34)
White 42 (62)
Bi-racial 3 (4)
Insurance
Medicaid/Medicare 25 (37)
Uninsured (Self pay/Hospital subsidy) 43 (63)
Diagnoses
Axis 1 mental illness
Any Axis 1 (non-substance use disorder) 62 (91)
Psychotic spectrum 4 (6)
Bipolar spectrum 11 (16)
Unipolar depression spectrum 45 (66)
Anxiety spectrum 22 (32)
PTSD 9 (13)
Axis 2 mental illness
Any personality disorder 25 (37)
Borderline 9 (13)
Anti-social 1 (2)
Personality disorder NOS 15 (22)
Axis 1 substance use disorder
Any substance use disorder 68 (100)
ETOH dependence 49 (72)
Opioid dependence 32 (47)
ETOH but not ppioid 36 (53)
Opioid but not ETOH 19 (28)
Both ETOH and ppioid 13 (19)
Benzodiazepine abuse/dependence 14 (21)
Cannabis abuse/dependence 24 (35)
Nicotine dependence 40 (59)
Stimulant (cocaine/amph) dependence 20 (29)
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injection phase. This included 2 patients with both opioid and
ETOH disorders that had been prescribed buprenorphine prior
to entering our clinic, 1 patient with both diagnosis that had
been prescribed buprenorphine in our clinic (prior to INTX),
and 4 others that had opioid disorders only, who were initially
prescribed buprenorphine, then converted to INTX in our
clinic. Clinical parameters of the post-injection treatment
phase, according to indication group are shown in Table 3.
There were no differences between the groups in treatment
days post-initial injection (F[2,65]¼ .35, NS), injections
delivered per patient (F[2,65]¼ .04, NS), or mean number
of days post-initial injection per injection (inter-injection
interval) (F[2,65]¼ .12, NS). The number of treatment service
encounters over the post-injection treatment phase (adjusted
by duration of the post-injection phase) trended differently
(but insigniﬁcantly F(2, 65)¼ 1.9, NS) according to group
so that patients with both ETOH and opioid addiction
used the most services (81.9þ 18.8/year) compared to 62.8þ
16.0/year for opioid only patients, and 46.5þ 7.2/year for ETOH
only patients.
Urine Drug Screening Outcomes
The mean number UDS collected per patient (counted as
sum of all collections including all 10 drug types) for each
group during the pre- versus post-injection phases, are
shown in Table 3. Although the total fraction of UDS tests
that were positive (for any substance) trended downward
for both groups with opioid disorders from the pre- to
post-injection phases (analyzed for the n¼ 43 patients who
had UDS tests in both the pre- and post-injection phases)
(Table 3), these changes only approached signiﬁcance (phase:
F[1,40]¼ 3.0, p¼ .09, NS); group: F[2,40]¼ 1.5, NS;
group x2009; phase F[2, 40]¼ 2.5, p¼ .09, NS). Similarly,
when focusing on ETG testing only (Fig. 1A; analyzed only
for the n¼ 21 patients that had ETG tests collected in
both the pre- and post-injection phases) the fraction of
positive ETG tests did not decline signiﬁcantly (phase:
F[1,19]¼ .34, NS) and did not differ signiﬁcantly according
to group ([F(1,19)¼ .28, NS]) or as a phase group
interaction (F[1,19]¼ .02, NS) . In contrast, when focusing
on opioid testing (Fig. 1B), analyzed for n¼ 42 patients that
had opioid tests collected in both the pre- and post-injection
phases, there was a signiﬁcant overall decline in the fraction of
positive opioid tests (phase: F[1,39]¼ 5.7, p< .05) on top of
an overall group difference where, as expected, groups with
opioid disorders had higher overall fractions of opioid
tests positive compared to patients with ETOH only (group:
F[2,39]¼ 6.0, p< .01). Changes in the percent of positive
opioid tests also varied by indication group attaining marginal
signiﬁcance (phase group: F[2,39]¼ 3.2, p¼ .05).
Prescription Drug Monitoring Database Outcomes
PDMP measures of opioid prescribing covering all cases
(N¼ 68), revealed signiﬁcant changes from pre- to post-
injection phases. Opioid prescriptions/year (Fig. 1C), while
being higher in the opioid groups (F[2,65]¼ 7.7, p¼ .001),
declined signiﬁcantly after the initial injection depending on
the diagnostic group (phase group: F[2,65]¼ 6.4, p< .01).
Post hoc analyses pinpointed signiﬁcant declines in opioid
prescriptions in only the opioid-only group (phase: F1,18¼
9.7, p< .01). Opioid pills dispensed/year (Fig. 1D) showed
indication group differences (group: F[2,65]¼ 5.2, p< .01),
with a signiﬁcant decreases post-injection (phase: F[1,65]¼
10.3, p< .01), that depended on the diagnostic group
(phase group: F[2,65]¼ 6.1, p< .01). Speciﬁcally, the
decline in opioid pills was signiﬁcant only in the opioid-
only addiction group (F[1,18]¼ 18.0, p< .001). The number
of different opioid types prescribed per patient (Fig. 1E), also
differed by group (F[2,65]¼ 5.7, p< .01), with overall
declines post-injection (phase: F[1,65]¼ 14.7, p< .001) that
were group-related (phase group: F[2,65]¼ 4.8, p< .05),
where in post hoc testing signiﬁcance was limited to the OP
group (F[1,18]¼ 16.7, p< .01). The number of prescribers
(Fig. 1F) was also different according to diagnostic group
(F[2,65]¼ 7.2, p< .01) and declined signiﬁcantly post-
injection (phase: F[1,65]¼ 19.8, p< .001), with a signiﬁcant
phase group interaction (F[2,65]¼ 4.5, p< .05). This
interaction was further speciﬁed by post hoc analysis as
being limited to the opioid-only patients (F[1,18]¼ 29.3,
p< .001). A similar pattern was found in analysis of number
of dispensing pharmacies (Fig. 1G: [group: (F(2,65)¼ 6.2,
p< .01; phase: F(1,65)¼ 28.6, p< .001; phase group:
F(2,65)¼ 5.6, p< .01]), where both opioid-only patients
TABLE 2. Frequencies of diagnostic comorbidities (within N¼68)
Diagnostic class(s)
# Diagnoses
per patient n (%)
Mental illnessa 0 5 (7)
1 27 (40)
2 21 (31)
3 13 (19)
4 2 (3)
Substance use disorders 0 0 (0)
1 14 (21)
2 16 (24)
3 20 (29)
4 15 (22)
5 3 (4)
Mental illnessþ substance 0 0 (0)
use D/Ob 1 1 (2)
2 6 (9)
3 17 (25)
4 17 (25)
5 10 (15)
6 6 (9)
7 9 (13)
8 2 (3)
aNon-substance use disorder, inclusive of all combinations of Axis 1 and 2;
ball comorbid combinations of Axis 1 (mental illness and substance use
disorder) and Axis 2.
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(phase: F[1,18]¼ 14.0, p< .01) and patients with opioid and
alcohol disorders (F[1,12]¼ 5.7, p< .05) showed signiﬁcant
declines.
DISCUSSION
This study demonstrates PDMP utility in treatment
outcome monitoring of patients with opioid addiction. We
show that repeated PDMP data collections can be used not
only to corroborate clinical diagnoses, but to gauge treatment
response. If paired routinely with UDS testing in clinical
practice, PDMP database inquiry may thus contribute to an
increasingly informative tool kit of objective measures to
compliment subjective (eg, craving) assessments, and other
more general psychiatric, medical, and functional measures for
guiding clinical decision-making and quantifying outcomes.
These ﬁndings build on prior research in the same clinic
using PDMP for determining the exposure of a mentally ill/
addicted population to hazardous controlled substance
prescribing, and for use as a diagnostic tool.11 This prior
study found that a majority of patients in the census had been
prescribed opioids over the year before addiction psychiatry
evaluation, and that PDMP data collected independent from
this evaluation was predictive of both opioid use disorders and
personality disorder diagnoses. The design and data collection
of the present study differed from the earlier 1 in 3major ways:
only patients receiving at least one INTX dose were included;
PDMP data was routinely incorporated into the diagnostic
workup of all patients; and, patients were grouped according
to INTX indication for repeated PDMP data analyses.
Nevertheless, both studies included patient populations that
were similar demographically: 54% to 58%were between ages
26–45 years; 51% to 59% were female; 55% to 62% were
white; 63% to 66% were uninsured. Frequencies of dual
diagnosis comorbidities (having an Axis 1 mental illness with
a concurrent substance disorder) were very high in both study
populations (80% to 91%, respectively). The densities and
patterns of dual diagnoses comorbidities, and racial/age
demographics of patients with opioid use disorders found
in the present study were also consistent with several
urban clinical samples and large scale epidemiological
surveys,2,7,8,21–25 indicating the present ﬁndings are likely
generalizable to many addiction treatment settings. Notably,
the rates of comorbid alcohol use disorders among patients
with opioid use disorders found in our sample (41%) were
comparable to recent population data showing that 58% of
patients with opioid use disorders have 12-month prevalence
rates of alcohol abuse or dependence.25
The 3 diagnostic group/repeated measures design and
cross-comparison with UDS testing provided helpful experi-
mental controls and an informative and yet credible pattern of
results. The 3 diagnostic groups did not differ by number of
days followed after initial injection, number of injections
given, inter-injection intervals, or number of clinical service
encounters. However, as expected, UDS tests that were
positive for opioids, and PDMP patterns of opioid prescribing,
did vary signiﬁcantly according to diagnostic group and
were mutually consistent by showing higher opioids in the
opioid-dependent groups compared to the ETOH-only group.
In effect, the ETOH-only group served as a naturalistic control
for examining the capacity of treatment to speciﬁcally
reduce opioid exposure in patients with opioid addiction,
and for demonstrating that PDMP monitoring is capable
of capturing this outcome in a way that is diagnostically
speciﬁc and expected. Accordingly, PDMP data revealed that
INTX-associated treatment had its most profound effects in
reducing opioid prescriptions, doses, opioid types, numbers
TABLE 3. INTX indication group characteristics
INTX dosing
Days post-injection per injection
Frequencies by range (days)
Vivitrol indication (n) Days post-injection Number of injections Mean <60 (60< 120) >120
ETOH 36 208 11 2.8 .3 97 11 12 17 7
OP 19 189 23 2.7 .6 100 15 6 7 6
BOTH 13 201 23 2.7 .6 108 22 6 2 5
24 26 18
UDS testing
Total indiv. drug testsa % Positiveb
Vivitrol indication (n) Pre Post (n) Pre Post
ETOH 36 13.4 1.8 16.2 2.8 22 6.5 1.8 7.0 1.9
OP 19 10.9 2.0 12.7 4.8 11 12.5 3.4 11.7 3.3
BOTH 13 13.2 2.8 16.8 4.3 10 16.3 5.3 6.7 3.5
aTotal number of individual tests collected (spanning possible selections of morphine, codeine, oxycodone, hydrocodone, buprenorphine, methadone, cocaine,
amphetamine, tetrahydrocannabinol, and ethylglucoronide); bpercent positive tests for those subjects tested both before and after initial injection.
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FIGURE 1. Urine drug test results (A and B), PDMPmeasures of opioid prescribing activity (C–E) and health care system involvement (F and G)
pre versus post initial injection. (A) Percent of positive ETG tests trended downward non-signiﬁcantly among the n¼ 21 subjects (ETOH, n¼ 18;
OP þ ETOH, n ¼ 3) that had ETG testing both before and after initial INTX injection. (B) Percent of positive opioid tests differed by group and
decreased post-injection among the n¼ 42 subjects (ETOH, n¼ 22; OP, n¼ 11; OPþ ETOH, n¼ 9) that had opioid testing both before and after
initial INTX injection (ETOH: Patients with alcohol without opioid use disorders; OP: patients with opioid but not alcohol use disorders; OPþETOH
patients with both alcohol and opioid use disorders). For all PDMP data (C–G) all N¼68 subjects are shown graphically and included in the
statistical analysis. (C) The number of opioid prescriptions (adjusted to annual rates), differed between groups and dropped speciﬁcally in the OP
group. (D) Annual adjusted numbers of opioid doses (normalized by Log base 2 transformation), differed by group, dropped overall, and in a
signiﬁcantly more robust way for the OP group. (E) Number of different types of opioids dispensed also differed by group, dropped overall, and in
a more robust way for the OP group. (F) The number of prescribers dispensing controlled substances, differed by group, dropped overall, and in a
signiﬁcantly more robust way for the OP group. (G) The number of pharmacies dispensing controlled substances, differed by group, dropped
overall, and in a signiﬁcantly robust way for the OP and the OPþETOH groups. Bars showmeansSEMS. Signiﬁcant results from ANOVAs are
noted where they occur (p< .05; p< .01; p .001).
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prescribers, and dispensing pharmacies in patients with opioid
use disorders uncomplicated by alcohol disorders. These
ﬁndings are in general agreement with studies indicating
that the presence of multiple addictions renders patients
more treatment refractory,26,27 suggesting the need for more
research into improving INTX efﬁcacy in patients with
comorbid opioid and alcohol disorders.
Both the strengths and limitations of the present study
design should be considered in interpreting these results. The
primary goal of the study was to demonstrate the utility of
PDMP for monitoring treatment outcomes in the context of a
treatment (INTX) that is already evidence-based and FDA
approved. Accordingly, it was not designed as a clinical
trial for INTX, and patients included in the study were
being treated for a number of concurrent psychiatric and
substances disorders using a range of different medications
and psychotherapies. So, INTX treatment in this study deign
served mainly as a discrete and certain temporal milestone to
demark a “before” and “after” phase of treatment initiation,
and was likely just one of a number of active therapeutic
ingredients producing the clinical improvement documented
by PDMP and UDS data. Future studies will need to discern
how different therapies for opioid and other addictions
and co-occurring mental illnesses produce efﬁcacies as
measured by PDMP data. A second major strength and
weakness of the present study was its naturalistic design.
Patients were not monetarily incentivized or diagnostically
selected (other than having an indication for INTX injection)
to participate in the research. Diagnostic workups and
treatment strategies were highly individualized with quite
variable, randomized use of UDS testing; greater standardi-
zation of UDS testing (ie, occurring in regular intervals,
or with the same frequencies among all subjects), and
uniformity of pre- and post-treatment intervals of PDMP
data capture are needed in future studies. Greater experi-
mental controls of treatment subgroup compositions in terms
of comorbid diagnoses, type and timing of treatment choices
or randomizations, and different mixes of insurance cover-
age, might produce more robust and/or nuanced effects in
terms of PDMP-measured outcomes.
In summary, this study is the ﬁrst to demonstrate the clinical
utility of PDMP data collection as an objective measure of
addiction treatment outcomes, and the ﬁrst to verify the
consistency of these data with UDS testing. These data lend
support to calls for PDMP utilization to be routine or even
mandatory in various practice contexts.28 The study also
illustrates what is likely to be a signiﬁcant range of public
health beneﬁts of addiction prevention and treatment services
that utilize PDMPs, for limiting unnecessary and potentially
harmful healthcare practices associated with overprescribing
of opioids.29,30 In a population of mentally ill-addicted
patients at risk for “Adverse Selection” phenomena,14
PDMP monitoring showed that addiction and dual diagnosis
treatment involving INTX objectively produced a signiﬁcant
decrease in exposure to prescribed opioids. This decrement
was likely accompanied, to some extent that we did not
measure, by reductions in costs associated with doctor’s visits,
medical diagnostic tests, pharmacy costs, and diversion of
prescription drugs that often accompany iatrogenic opioid
prescribing.7,30,31 These ﬁndings thus suggest a remarkable, if
indirect effect of addiction treatment, beyond individual
patients, on the practices of outside physicians and health care
systems that may inadvertently be contributing to addictions
and overdose deaths. Along with educational and regulatory
efforts designed to limit over-prescribing of opioids and other
additive drugs, expanding psychiatric and dual diagnosis
treatment services that incorporate PDMP utilization should
be considered key strategies in reducing the prescription drug
epidemic.
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